
QuikPath Overview

The Problem and Opportunity



Infectious disease testing is time consuming and expensive, requiring skilled professionals – often resulting in anxiety and delays in treatment.

Case in point: Covid-19. Six months after being declared a pandemic, COVID-19 testing rates are only 19% of that recommended by WHO. Unmet demand is estimated to be 2.7B tests, growing at 17.6% Y-o-Y.



At, QuikPath, our mission is to make diagnostics quicker, accessible, convenient and affordable — without compromising on sensitivity or specificity. Given the global; situation, our **first focus is Covid-19**

Our Solution

QuikPath's technology is based on LAMP RT-PCR. It is easily adaptable for a variety of diseases. Applying it for COVID-19, we have developed a Point-of-Care Test that can be performed by anyone anywhere and gives results < 40 mins.

100x

72x

50x

than lab-based tests

than lab-based test

Our Innovation and Advantage

Patent pending design. Sensitivity of 10 viral load per ul

BIOLOGY CARTRIDGE Proprietary test Designed by Dr. components Anansa Accuracy comparable to Closed design that lab-PCR and better than can be used by other POC test anyone: RNA amplification occurs Multiple viral strains internally in single detected step PATENT FILED

Affordable

Accurate

Accessible

Our Products



QuikPath RAPID	QuikPath RAPID Se	lf
Fluorescence detection	Colorimetric	
< \$20 / test	< \$20 / test	
10 tests / run	1 test / run	
> 90% sensitivity	> 90% sensitivity	-

Two products, each comprising a patent pending cartridge (which contains a proprietary reagent mix to detect viral RNA) and an analyzer to serve as heat bath

Go-to-Market and Progress



- Provisional patent filed in Singapore and India
- Final stage of product review by the HSA, Singapore
- CE mark certification planned for Oct-Nov 2020
- Launch in in Nov 2020 in India, ASEAN and Brazil
- Distributor and OEM discussions in progress

The Road Ahead: Beyond COVID-19

In the future, we intend to design and sell cartridges to test for infectious diseases such as Influenza (panel), TB, HIV, Dengue and STI's and cater to F&B industry by developing test for contamination in food and beverages. All tests will be compatible with existing Analyzers.

Network from COVID-19 would allow us to expand and scale operations efficiently.

The Ask

\$500K
Seed Funding for Product Launch

Contact Us

QuikPath Pte. Ltd

@ @71 Ayer Rajah Crescent, #06-01, Singapore

Contact: info@quikpath.sg

Diagnostics. Accurate. Accessible. Affordable